Biomarkers /
ROBO1
Overview
ROBO1 is altered in 0.44% of all cancers with diffuse large B-cell lymphoma, not otherwise specified, conventional glioblastoma multiforme, mantle cell lymphoma, cutaneous melanoma, and B-cell lymphoblastic leukemia/lymphoma having the greatest prevalence of alterations [3].
The most common alterations in ROBO1 are ROBO1 Loss (0.17%), ROBO1 R501* (0.20%), ROBO1 D499Y (0.05%), ROBO1 E142K (0.05%), and ROBO1 K1051Q (0.18%) [3].
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.